Top

Published in:

01-11-2004 | Original Article

Virosomes as new carrier system for cancer vaccines

Authors: Ruth Schwaninger, Ernst Waelti, Paul Zajac, Antoinette Wetterwald, Dominique Mueller, Claude D. Gimmi

Published in: Cancer Immunology, Immunotherapy | Issue 11/2004

Abstract

HER-2/neu, a tumor-associated antigen (TAAg), plays a critical role in oncogenesis of various tumor types, and its selective overexpression by malignant tumor cells makes it an ideal target for immunotherapy. A prerequisite for clinical vaccines is the construction of safe and highly immunogenic reagents able to generate efficient immune responses against TAAg. Previous protein vaccines, consisting of the extracellular domain of HER-2/neu (p^NeuECD), were shown to elicit an immune response that did not provide protection from transplantable tumors expressing HER-2/neu. Here we showed that virosomes, which consist of reconstituted viral envelopes without viral genetic material, can act as a carrier and an adjuvant for a truncated protein p^NeuECD . Mice vaccinated with p^NeuECD either encapsulated in virosomes or bound to the virosomal membrane (Vir-p^NeuECD), generated rNeu-specific humoral and cytotoxic immune responses. In addition, Vir-p^NeuECD induced significant tumor rejection and additionally did not lead to delayed tumor formation when compared with free p^NeuECD in complete Freund’s adjuvant. There was no difference between the virosomal constructs. Taken together these results suggest that virosomes, as clinically approved safe vaccines, can be used to elicit both humoral and cell-mediated responses against TAAg and induce tumor rejection. Our model is providing important preclinical data to design human vaccination trials for patients with tumors overexpressing HER-2/neu, either as a primary vaccination or as a boost in combination with other vaccines in a context of an adjuvant treatment plan.

Kapitanovic S, Radosevic S, Kapitanovic M, Ferencic Z, Tavassoli M, Primorac D, Spaventi R (1997) The expression of p185 (HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112:1103–1113PubMed

Ross J, Sheehan C, Hayner-Buchan A, Ambros R, LKallakury B, Kaufman R, Fisher H, Rifkin M, Muraca P (1997) Prognostic significance of HER-2/neu gene amplification status by fkluorescence in situ hybridization of prostate cancer. Cancer 79:2162–2170CrossRefPubMed

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–181PubMed

Tsai C, Chang K, Perng R, Mitsudomi T, Chen M, Gazder A (1993) Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell line with HER-2/neu gene expression bvut not with ras gene mutations. J Natl Cancer Inst 85:897–901PubMed

Disis M, Knutson K, Schiffman K, Rinn K, McNeel D (2000) Pre-existing immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 62:245–252CrossRefPubMed

Disis M, Pupa S, Gralow J, Dittadi R, Menard S, Cheever M (1997) High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15:3363–3367PubMed

Moss B (1996) Genetically engineered poxvirus for recombinant gene expression, vaccination and safety. Proc Natl Acad Sci U S A 93:11341–11348CrossRefPubMed

Zajac P, Schütz A, Oertli D, Noppen C, Schaefer C, Heberer M, Süpagnoli G, Marti W (1998) Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules. Cancer Res 58:4567–4571PubMed

Daemen T, De Haan A, Arkema A, Wilschut J (1998) Liposomes and virosomes as immunoadjuvant and antigen-carrier systems in vaccine formulation. Med Appl Liposomes 117–143

10.

Hernandez L, Hoffmann L, Wolfsberg T, White J (1996) Virus-cell and cell–cell fusion. Annu Rev Cell Dev Biol 12:627–661CrossRefPubMed

11.

Bungener L, Idema J, Veer W, Huckriede A, Daemen T, Wilschut J (2002) Virosomes in vaccine development: induction of cytotoxic lymphocyte activity with virosome-encapsulated protein antigens. J Liposome Res 12:155–163CrossRefPubMed

12.

Daemen T, Huckenriede A, Bungener L, Wilschut J (2000) Virosomes as an antigen delivery system. J Liposome Res 10:329–338

13.

Peppelenbosch M, DeSmedt M, Pynaert G, Deventer S, Grooten J (2000) Macrophages present pinocytosed exogenous antigen via MHC class I whereas antigen ingested by receptor-mediated endocytosis is present via MHC class II. J Immunol 165:1984–1991PubMed

14.

Cusi MG, Zurbriggen R, Valassina M, Bianchi S, Durrer P, Valensin P, Donati M, Glück R (2000) Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity. Virololgy 277:111–118CrossRef

15.

Morrison BW (1994) The genetics of breast cancer. Hematol/Oncol Clin North Am 8:15–28

16.

Bargmann CI, Hung M, Weinberg AW (1986) The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226–230PubMed

17.

Huang L, Connor J, Wang C (1987) pH-sensitive immunoliposomes. Methods Enzymol 149:88–90PubMed

18.

Waelti ER, Glück R (1998) Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes). Int J Cancer 77:728–733CrossRefPubMed

19.

Skehel JJ, Schild GC (1971) The polypeptide composition of influenza-A virus. Virology 44:396–408CrossRefPubMed

20.

Falkner FG, Moss B (1988) Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol 62:1849–1854PubMed

21.

Tsung K, Yim J, Buller MWML, Norton JA (1996) Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light. J Virol 70:165–171PubMed

22.

Céfai D, Favre L, Buri C, Wattendorf E, Marti A, Jaggi R, Gimmi C (2000) The role of Fas ligand expression in promoting escape from immune rejection in an in vivo spontaneous tumor model. Int J Cancer 91:529–537

23.

Céfai D, Morrison B, Skell A, Favre L, Balli M, Leunig M, Gimmi C (1999) Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer. Int J Cancer 83:393–400CrossRefPubMed

24.

Krieg AS, Yi A, Matson S, Waldschmidt TJ, Teasdale BGAR, Koretzky GA, Klinman DM (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546–549PubMed

25.

Hunziker I, Zurbriggen R, Glueck R, Engler O, Reichen J, Dai W (2001) Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol Immunol 38:475–484CrossRefPubMed

26.

Bernard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson K, Disis M (2002) Vaccination against the HER-2/neu oncogenic protein. Endocr Relat Cancer 9:33–44PubMed

27.

Disis M, Gooley T, Rinn K, Davis D, Piepkorn M, Cheever M (2002) Generation of T cell immunity to HER-2/neu protein after active immunization with HER-/neu peptide-based vaccines. J Clin Oncol 20:2624–2632CrossRefPubMed

28.

Tzahar E, Yarden Y (1998) The ErbB-2/Her2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta 1377:M25–M37PubMed

29.

Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, Cheever MA (1994) Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54:16–20PubMed

30.

Chen Y, Hu D, Eling D, Robbins J, Kipps TJ (1998) DNA Vaccines encoding full-length or truncated neu induce protective immunity against neu-expressing mammary tumors. Cancer Res 58:1965–1971PubMed

31.

Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini P, Landuzzi L, Colombo M, Giovarelli M, Musiani P, Forni G (2000) DNA vaccination against rat HER-2/neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165:5133–5142PubMed

32.

Wei W, Shi W, Galy A, Lichlyter A, Hernandez S, Groner B, Heilbrun L, Jones R (1999) Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA Int J Cancer 81:748–754

33.

Huckriede A, Bungener L, ter Veer W, Holtrop M, Daemen T, Palache A, Wilschut J (2003) Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine 21:925–931CrossRefPubMed

34.

Correale P, Cusi M, Sabatino MM, Pozzessere LD, Nencini C, Valensin P, Petrioli R, Giorgi G, Zurbriggen R, Gluck R, Francini G (2001) Tumor-associated antigen-specific cytotoxic T cell response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes. Eur J Cancer 37:2097–2103CrossRefPubMed

35.

Morse M, Clay T, Colling K, Hobeika A, Grabsteiner K, Cheever M, Lyerly H (2003) HER2 dendritic cell vaccines. Clin Breast Cancer Suppl 4:164–172

36.

Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109–2117PubMed

37.

Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis M, Cheever M (1997) Identification of HER-2/neu CTL epitopes using double transgenic mice expressing HLA-A2 and human CD8. Hum Immunol 52:109–118CrossRefPubMed

38.

Yoshino I, Geodegebuure PS, Peoples GE, Parikh AS, DiMaio JM, Lyerly HK, Gazdar AF, Eberlein TJ (1994) HER2/neu-derived peptides are shared antigens among non-small cell lung cancer and ovarian cancer. Cancer Res 54:3387–3390PubMed

39.

Disis ML, Gralow JR, Bernhard H, Hand SL, Rubin WD, Cheever MA (1996) Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein. J Immunol 156:3115–3158

40.

Zaks T, Rosenberg S (1998) Immunization with a peptide epitope (p369–377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 58:4902–4908PubMed

41.

Taylor P, Gerder M, Moros Z, Feldmann M (1996) Humoral and cellular responses raised against the human HER2 oncoprotein are cross-reactive with the homologous product of the neu rpoto-oncogene, but do not protect rats against B104 tumors expressing mutated neu. Cancer Immunol Immunother 42:179–184CrossRefPubMed

42.

Foy T, Bannink J, Sutherland R, McNeill P, Moulton G, Smith J, Cheever M, Grabstein K (2001) Vaccination with HER-2/neu DNA or protein subunits protects against growth of a HER-2/neu expressing murine tumor. Vaccine 19:2598–2606PubMed

43.

Glueck R, Mischler R, Finkel B, Que J, Scarpa B, Cryz S (1994) Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344:160–163CrossRefPubMed

44.

Holzer B, Hatz C, Schmidt-Sissolak D, Glueck R, Althaus B, Egger M (1996) Immunogenicity and adverse effects of inactivated virosome versus alum-absorbed hepatitis A vaccine: a randomised controlled trial. Vaccine 14:982–986CrossRefPubMed

45.

Poeltl-Frank F, Zurbriggen R, Helga A, Stuart F, Robinson J, Glueck R (1999) Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide based vaccine. Clin Exp Immunol 117:496–503CrossRefPubMed

Title: Virosomes as new carrier system for cancer vaccines
Authors: Ruth Schwaninger
Ernst Waelti
Paul Zajac
Antoinette Wetterwald
Dominique Mueller
Claude D. Gimmi
Publication date: 01-11-2004
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 11/2004
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-004-0545-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2004

Cancer gene therapy: new horizons in the East

Generation of human tumor-specific CTLs in HLA-A2.1–transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors

Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation?

Lower percentages of monocytes with CD80, CD86 and HLA-DR molecule expression in pediatric cancer

Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells

Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer